Published in J Virol on November 01, 2002
Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol (2003) 4.47
Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci U S A (2006) 4.14
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A (2003) 4.03
The structural biology of HIV assembly. Curr Opin Struct Biol (2008) 3.71
Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc Natl Acad Sci U S A (2003) 3.20
Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. EMBO J (2007) 3.17
Structure and assembly of immature HIV. Proc Natl Acad Sci U S A (2009) 2.51
In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol (2006) 1.70
Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J Virol (2004) 1.69
Analysis of the initiating events in HIV-1 particle assembly and genome packaging. PLoS Pathog (2010) 1.66
Conformation of the HIV-1 Gag protein in solution. J Mol Biol (2006) 1.59
Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay. J Virol (2005) 1.55
The retroviral capsid domain dictates virion size, morphology, and coassembly of gag into virus-like particles. J Virol (2005) 1.52
Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging. Protein Sci (2005) 1.49
Novel approaches to inhibiting HIV-1 replication. Antiviral Res (2009) 1.48
Flexibility in the P2 domain of the HIV-1 Gag polyprotein. Protein Sci (2004) 1.33
Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting. J Mol Biol (2008) 1.31
Virus assembly, allostery and antivirals. Trends Microbiol (2010) 1.26
Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. J Virol (2005) 1.21
The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release. J Virol (2004) 1.18
On the role of the SP1 domain in HIV-1 particle assembly: a molecular switch? J Virol (2011) 1.17
The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles. Retrovirology (2011) 1.13
Conserved and variable features of Gag structure and arrangement in immature retrovirus particles. J Virol (2010) 1.09
HIV type 1 Gag as a target for antiviral therapy. AIDS Res Hum Retroviruses (2011) 1.08
Protease cleavage leads to formation of mature trimer interface in HIV-1 capsid. PLoS Pathog (2012) 1.07
The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. Virology (2010) 1.07
Structural and functional insights into the HIV-1 maturation inhibitor binding pocket. PLoS Pathog (2012) 1.06
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One (2007) 1.06
The host protein Staufen1 interacts with the Pr55Gag zinc fingers and regulates HIV-1 assembly via its N-terminus. Retrovirology (2008) 1.04
The host protein Staufen1 participates in human immunodeficiency virus type 1 assembly in live cells by influencing pr55Gag multimerization. J Virol (2007) 1.03
A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat. Antimicrob Agents Chemother (2011) 1.01
Mutations in the spacer peptide and adjoining sequences in Rous sarcoma virus Gag lead to tubular budding. J Virol (2008) 1.00
Design of in vitro symmetric complexes and analysis by hybrid methods reveal mechanisms of HIV capsid assembly. J Mol Biol (2011) 0.97
Important role for the CA-NC spacer region in the assembly of bovine immunodeficiency virus Gag protein. J Virol (2004) 0.93
Basic residues of the retroviral nucleocapsid play different roles in gag-gag and Gag-Psi RNA interactions. J Virol (2004) 0.93
3D visualization of HIV virions by cryoelectron tomography. Methods Enzymol (2010) 0.89
Higher-order structure of the Rous sarcoma virus SP assembly domain. J Virol (2014) 0.89
How HIV-1 Gag assembles in cells: Putting together pieces of the puzzle. Virus Res (2014) 0.88
NMR relaxation studies of an RNA-binding segment of the rous sarcoma virus gag polyprotein in free and bound states: a model for autoinhibition of assembly. Biochemistry (2010) 0.85
Identification of HIV-1 inhibitors targeting the nucleocapsid protein. J Med Chem (2012) 0.85
Crystal structure of an HIV assembly and maturation switch. Elife (2016) 0.85
Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process. Mol Biol Int (2012) 0.85
Dimerization of the SP1 Region of HIV-1 Gag Induces a Helical Conformation and Association into Helical Bundles: Implications for Particle Assembly. J Virol (2015) 0.84
A temporospatial map that defines specific steps at which critical surfaces in the Gag MA and CA domains act during immature HIV-1 capsid assembly in cells. J Virol (2014) 0.82
Incorporation of human immunodeficiency virus type 1 reverse transcriptase into virus-like particles. J Virol (2007) 0.82
Cysteine 95 and other residues influence the regulatory effects of Histidine 69 mutations on Human Immunodeficiency Virus Type 1 protease autoprocessing. Retrovirology (2010) 0.81
Role of Mason-Pfizer monkey virus CA-NC spacer peptide-like domain in assembly of immature particles. J Virol (2014) 0.80
Efficient production of HIV-1 virus-like particles from a mammalian expression vector requires the N-terminal capsid domain. PLoS One (2011) 0.80
A new ensemble coevolution system for detecting HIV-1 protein coevolution. Biol Direct (2015) 0.80
A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein. Virology (2006) 0.79
Morphology and ultrastructure of retrovirus particles. AIMS Biophys (2015) 0.79
HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors. Curr Top Med Chem (2016) 0.78
Pharmacological intervention of HIV-1 maturation. Acta Pharm Sin B (2015) 0.78
Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396. J Virol (2016) 0.77
Conserved Interaction of Lentiviral Vif Molecules with HIV-1 Gag and Differential Effects of Species-Specific Vif on Virus Production. J Virol (2017) 0.75
Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors. PLoS Pathog (2016) 0.75
Prediction of protein secondary structure at better than 70% accuracy. J Mol Biol (1993) 17.53
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell (2001) 12.00
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05
Combining evolutionary information and neural networks to predict protein secondary structure. Proteins (1994) 9.97
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell (1989) 9.68
PHD: predicting one-dimensional protein structure by profile-based neural networks. Methods Enzymol (1996) 9.10
HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med (2001) 8.38
HIV-1 gag proteins: diverse functions in the virus life cycle. Virology (1998) 7.32
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell (1996) 6.74
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
Assembly and analysis of conical models for the HIV-1 core. Science (1999) 6.35
Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science (1997) 6.10
Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A (2001) 5.83
Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature (2000) 5.60
Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol (1995) 5.21
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc Natl Acad Sci U S A (1996) 4.83
Viral late domains. J Virol (2002) 4.51
The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol (1994) 3.95
Crystal structure of dimeric HIV-1 capsid protein. Nat Struct Biol (1996) 3.93
Improved prediction of protein secondary structure by use of sequence profiles and neural networks. Proc Natl Acad Sci U S A (1993) 3.92
Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol (1994) 3.85
Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol (1998) 3.84
The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J Virol (1995) 3.80
Virus maturation by budding. Microbiol Mol Biol Rev (1998) 3.78
Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol (2000) 3.77
Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol (1994) 3.47
In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus. Eur J Biochem (1997) 3.38
In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J Virol (1999) 3.34
A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly. J Virol (1998) 3.06
A conformational switch controlling HIV-1 morphogenesis. EMBO J (2000) 2.86
Structures of the HIV-1 capsid protein dimerization domain at 2.6 A resolution. Acta Crystallogr D Biol Crystallogr (1999) 2.77
Analysis of the assembly function of the human immunodeficiency virus type 1 gag protein nucleocapsid domain. J Virol (1998) 2.71
Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J Virol (1995) 2.56
Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA. J Virol (2000) 2.46
Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. EMBO J (1999) 2.33
Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation. Virology (1993) 2.20
Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol (2001) 2.17
Kinetic analysis of human immunodeficiency virus type 1 assembly reveals the presence of sequential intermediates. J Virol (2000) 2.11
Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. J Virol (1994) 1.99
The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. J Virol (1998) 1.91
Mapping and characterization of the N-terminal I domain of human immunodeficiency virus type 1 Pr55(Gag). J Virol (2000) 1.90
A multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free system. J Cell Biol (1997) 1.89
Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells. Virology (1998) 1.85
Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation. J Virol (1997) 1.83
Detection of a trimeric human immunodeficiency virus type 1 Gag intermediate is dependent on sequences in the matrix protein, p17. J Virol (1998) 1.66
Roles of matrix, p2, and N-terminal myristoylation in human immunodeficiency virus type 1 Gag assembly. J Virol (2000) 1.55
Dynamic interactions of the Gag polyprotein. Curr Top Microbiol Immunol (1996) 1.53
Recent advances and remaining problems in HIV assembly. AIDS (1998) 1.46
Gag precursors of HIV and SIV are cleaved into six proteins found in the mature virions. J Med Primatol (1990) 1.35
Identification of a minimal HIV-1 gag domain sufficient for self-association. Virology (2002) 1.01
Cotransfection of mutated forms of human immunodeficiency virus type 1 Gag-Pol with wild-type constructs can interfere with processing and viral replication. J Hum Virol (1999) 0.90
Hydrophobic amino acids in the human immunodeficiency virus type 1 p2 and nucleocapsid proteins can contribute to the rescue of deleted viral RNA packaging signals. J Virol (2001) 0.86
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res (2012) 4.45
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell (2004) 3.73
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2003) 3.60
The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem (2004) 3.27
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS (2006) 2.77
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol (2006) 2.32
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother (2006) 2.23
Whither or wither microbicides? Science (2008) 2.17
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS (2003) 2.11
A stomatin-domain protein essential for touch sensation in the mouse. Nature (2006) 2.08
Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother (2003) 2.04
Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol (2005) 2.02
The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol (2009) 2.00
Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A (2013) 1.98
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol (2011) 1.95
Counting individual DNA molecules by the stochastic attachment of diverse labels. Proc Natl Acad Sci U S A (2011) 1.89
Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89
APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J Biol Chem (2007) 1.87
Increased serum and urinary microRNAs in children with idiopathic nephrotic syndrome. Clin Chem (2013) 1.86
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol (2002) 1.84
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother (2002) 1.82
Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol (2008) 1.79
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS (2003) 1.78
Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol (2013) 1.76
Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol (2002) 1.75
The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol (2007) 1.74
Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function. Cell (2012) 1.73
Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis (2011) 1.70
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology (2013) 1.66
The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A (2008) 1.64
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (2004) 1.61
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol (2007) 1.61
Identification and characterization of Bph14, a gene conferring resistance to brown planthopper in rice. Proc Natl Acad Sci U S A (2009) 1.60
Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? Retrovirology (2004) 1.59
Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol (2011) 1.58
Drug treatment of oral submucous fibrosis: a review of the literature. J Oral Maxillofac Surg (2009) 1.58
RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol (2010) 1.55
Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res (2011) 1.55
Assessment of long-range correlation in time series: how to avoid pitfalls. Phys Rev E Stat Nonlin Soft Matter Phys (2006) 1.55
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther (2003) 1.53
The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Invest (2004) 1.50
High resolution discovery and confirmation of copy number variants in 90 Yoruba Nigerians. Genome Biol (2009) 1.49
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol (2010) 1.46
Complexity measures of brain wave dynamics. Cogn Neurodyn (2011) 1.45
RNA interference-mediated downregulation of hypoxia-inducible factor-1α inhibits angiogenesis and survival of oral squamous cell carcinoma in vitro and in vivo. Eur J Cancer Prev (2012) 1.45
Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J Biol Chem (2012) 1.45
Culturomics meets random fractal theory: insights into long-range correlations of social and natural phenomena over the past two centuries. J R Soc Interface (2012) 1.44
Selective inflammatory pain insensitivity in the African naked mole-rat (Heterocephalus glaber). PLoS Biol (2008) 1.43
The XVI International Conference on AIDS: the place to be! Retrovirology (2006) 1.39
Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci U S A (2011) 1.39
Entropies of negative incomes, Pareto-distributed loss, and financial crises. PLoS One (2011) 1.38
Association of RNA helicase a with human immunodeficiency virus type 1 particles. J Biol Chem (2006) 1.37
Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther (2003) 1.35
The interaction between HIV-1 Gag and human lysyl-tRNA synthetase during viral assembly. J Biol Chem (2003) 1.35
Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS (2012) 1.35
Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology (2007) 1.35
Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology (2010) 1.34
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med (2006) 1.34
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol (2010) 1.32
Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region. J Virol (2007) 1.31
Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis (2009) 1.30
Chemoprophylaxis of HIV infection: moving forward with caution. J Infect Dis (2006) 1.28
Retrovirus-specific packaging of aminoacyl-tRNA synthetases with cognate primer tRNAs. J Virol (2002) 1.27
Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev (2008) 1.27
Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. J Int Assoc Physicians AIDS Care (Chic) (2003) 1.27
Facilitating joint chaos and fractal analysis of biosignals through nonlinear adaptive filtering. PLoS One (2011) 1.26
Role of RNA in facilitating Gag/Gag-Pol interaction. J Virol (2002) 1.25
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother (2006) 1.25
Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS (2007) 1.24
Apolipoprotein c1 association with hepatitis C virus. J Virol (2008) 1.24
Rapid localization of Gag/GagPol complexes to detergent-resistant membrane during the assembly of human immunodeficiency virus type 1. J Virol (2003) 1.23
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
The role of unintegrated DNA in HIV infection. Retrovirology (2011) 1.23
Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology (2002) 1.22
Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother (2013) 1.21
The effect of tranexamic acid on blood loss in orthognathic surgery: a meta-analysis of randomized controlled trials. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 1.21
Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. J Virol (2005) 1.21
Mirk regulates the exit of colon cancer cells from quiescence. J Biol Chem (2009) 1.20
Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS (2014) 1.19
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr (2004) 1.19
Effect of altering the tRNA(Lys)(3) concentration in human immunodeficiency virus type 1 upon its annealing to viral RNA, GagPol incorporation, and viral infectivity. J Virol (2002) 1.18
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology (2013) 1.18
Antiretroviral therapy : optimal sequencing of therapy to avoid resistance. Drugs (2008) 1.17
Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother (2009) 1.17
HIV-1 modulates the tRNA pool to improve translation efficiency. Mol Biol Evol (2011) 1.16
Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer. J Biol Chem (2010) 1.16